GO:0000253 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000253 describes a NADP+-dependent oxidoreductase activity that converts a 3-beta-hydroxyl sterol to a 3-oxosterol, generating NADPH and H+.
• The activity is a core component of the bifunctional 3-beta-hydroxysteroid dehydrogenase/isomerase (3-beta-HSD) enzyme family, which also catalyzes the isomerization of delta-5 to delta-4 steroids.
• Human type 1 3-beta-HSD (HSD3B1) and type 2 (HSD3B2) are the principal enzymes carrying this activity in steroidogenic tissues [1,2].
• The reaction is essential for the biosynthesis of all classes of steroid hormones, including progesterone, androgens, estrogens, and corticosteroids [2,5].
• Coenzyme specificity for NADP+ is determined by specific residues in the Rossmann-fold domain of the enzyme.
• Dysregulation of 3-beta-HSD activity is linked to endocrine disorders, androgen excess, and steroid-dependent cancers [2,5].
Description
GO:0000253, 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity, is a molecular function that catalyzes the reversible oxidation of a 3-beta-hydroxyl group on a sterol substrate to a 3-oxosterol, using NADP+ as the electron acceptor and producing NADPH and H+. This activity is a critical step in steroid hormone biosynthesis, enabling the conversion of delta-5-3-beta-hydroxysteroids such as pregnenolone and dehydroepiandrosterone (DHEA) into their delta-4-3-keto counterparts, progesterone and androstenedione, respectively. The reaction is typically performed by bifunctional 3-beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase (3-beta-HSD) enzymes, which couple the dehydrogenase activity to an isomerase activity in a single polypeptide chain. Researchers study GO:0000253 to understand the molecular basis of steroidogenesis, the structural determinants of coenzyme specificity, and the role of 3-beta-HSD enzymes in endocrine pathologies and steroid-dependent cancers [1,2,5]. The activity is also a target for pharmacological modulation, as its inhibition can alter androgen and estrogen production.
3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity At A Glance
| GO ID | GO:0000253 |
|---|---|
| GO term | 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity |
| Ontology | molecular_function |
| Synonym | 3beta-hydroxy-steroid:NADP+ 3-oxidoreductase; 3-keto-steroid reductase activity; 3-keto sterol reductase activity; 3-KSR activity |
| Definition | Catalysis of the reaction: a 3-betahydroxyl sterol + NADP+ = a 3-oxosterol sterol + NADPH + H+. |
| Major function | Oxidation of 3-beta-hydroxyl sterols to 3-oxosterols using NADP+ as cofactor, a key step in steroid hormone biosynthesis. |
| Cofactor | NADP+ (nicotinamide adenine dinucleotide phosphate, oxidized form) |
| Substrate | 3-beta-hydroxyl sterols (e.g., pregnenolone, DHEA, androstenediol) |
| Product | 3-oxosterol sterols (e.g., progesterone, androstenedione, testosterone) and NADPH + H+ |
| Enzyme family | 3-beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase (3-beta-HSD) family |
What Is GO:0000253?
In simple terms, GO:0000253 is the enzyme activity that removes hydrogen from a 3-beta-hydroxyl group on a steroid molecule, using NADP+ as a cofactor, to create a 3-keto (oxo) group and release NADPH and a proton. The reaction is reversible and is part of the larger 3-beta-HSD enzyme complex that also isomerizes the double bond from the 5-ene position to the 4-ene position, yielding a delta-4-3-keto steroid.
Why Is 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity Important in Cell Biology?
GO:0000253 is essential for the biosynthesis of all steroid hormones, as it catalyzes the oxidative conversion of delta-5-3-beta-hydroxysteroids to delta-4-3-ketosteroids, a committed step in the production of glucocorticoids, mineralocorticoids, androgens, and estrogens. The activity is carried out by 3-beta-HSD enzymes, which are expressed in the adrenal cortex, gonads, placenta, and other peripheral tissues. Defects in 3-beta-HSD activity are associated with endocrine disorders such as congenital adrenal hyperplasia, polycystic ovary syndrome, and androgen excess, while overexpression has been implicated in steroid-dependent cancers such as breast and prostate cancer [2,5]. Understanding the molecular mechanism and regulation of this activity is therefore critical for developing targeted therapies that modulate steroidogenesis.
• Catalyzes a rate-limiting step in the biosynthesis of progesterone, androgens, estrogens, and corticosteroids.
• Enables the conversion of delta-5 steroids to delta-4 steroids, a prerequisite for downstream steroidogenic enzymes.
• Determines the balance between active and inactive steroid hormones in peripheral tissues.
• Provides a target for imidazole-based drugs such as ketoconazole, which can inhibit steroidogenesis.
• Plays a role in the local production of androgens in prostate and breast tissues, contributing to cancer progression.
• Is essential for adrenal steroidogenesis, as demonstrated by the presence of 3-beta-HSD in adrenal cortex mitochondria and microsomes.
• Its coenzyme specificity for NADP+ is a key structural feature that can be engineered for biotechnological applications.
• Dysregulation is linked to disorders of sexual development and endocrine hypertension.
• The activity is conserved across species, from rodents to humans, making animal models valuable for research.
• Modulation of this activity can influence the pharmacokinetics of steroid drugs and the efficacy of hormone therapies.
What Happens During 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity?
Substrate Binding and Orientation
In simple terms: The enzyme grabs a steroid molecule and positions it so that its 3-beta-hydroxyl group is ready for a chemical reaction.
The 3-beta-HSD enzyme binds a 3-beta-hydroxyl sterol substrate, such as pregnenolone or DHEA, in a hydrophobic pocket. Structural studies of human type 1 3-beta-HSD have identified key residues that recognize the steroid nucleus and orient the 3-beta-hydroxyl group toward the catalytic site. The substrate is held in place by hydrogen bonds and hydrophobic interactions, ensuring stereospecificity for the 3-beta configuration.
Hydride Transfer to NADP+
In simple terms: The enzyme removes a hydrogen from the steroid and transfers it to NADP+, turning it into NADPH.
The catalytic mechanism involves the transfer of a hydride ion from the 3-beta-hydroxyl group of the steroid to the nicotinamide ring of NADP+, which is bound in a Rossmann-fold domain. This oxidation step converts the 3-beta-hydroxyl to a 3-keto group and reduces NADP+ to NADPH, releasing a proton (H+). Site-directed mutagenesis has revealed that specific residues, such as those in the coenzyme-binding pocket, are critical for NADP+ specificity over NAD+.
Isomerization of the Double Bond
In simple terms: After the oxidation, the enzyme rearranges the double bond in the steroid ring to form a delta-4-3-keto steroid.
In the bifunctional 3-beta-HSD enzyme, the dehydrogenase activity is coupled to an isomerase activity that catalyzes the migration of the double bond from the 5-ene position to the 4-ene position, yielding a delta-4-3-keto steroid such as progesterone or androstenedione. This isomerization is essential for the subsequent steps in steroid hormone biosynthesis, as delta-4-3-keto steroids are the substrates for downstream enzymes like 17-alpha-hydroxylase and 5-alpha-reductase.
Product Release and Enzyme Turnover
In simple terms: The enzyme releases the finished steroid product and NADPH, then resets to start another reaction.
Following the isomerization, the product (e.g., progesterone) and NADPH are released from the enzyme, allowing the enzyme to undergo another catalytic cycle. The reaction is reversible, and the equilibrium can be influenced by the availability of NADP+ and NADPH. The enzyme's activity can be modulated by phospholipids and other cellular factors, as shown in rat testicular studies.
Key Genes Involved in GO:0000253 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity
The following genes encode enzymes that possess 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity or are directly involved in the reaction pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HSD3B1 | Encodes human type 1 3-beta-HSD, a bifunctional enzyme with dehydrogenase and isomerase activities; primarily expressed in placenta and peripheral tissues. | Key target for studying steroidogenesis in placenta and hormone-dependent cancers; structural studies of coenzyme specificity. |
| HSD3B2 | Encodes human type 2 3-beta-HSD, expressed in adrenal cortex and gonads; essential for cortisol and aldosterone synthesis. | Mutations cause congenital adrenal hyperplasia; model for endocrine disorders. |
| HSD3B3 | Encodes a 3-beta-HSD isoform with truncated structure, may lack dehydrogenase activity. | Less studied; potential regulatory role in steroidogenesis. |
| HSD3B4 | Encodes a 3-beta-HSD isoform expressed in liver and other tissues. | May contribute to peripheral steroid metabolism. |
| HSD3B5 | Encodes a 3-beta-HSD isoform in rodents, involved in androgen synthesis. | Used in animal models of steroidogenesis. |
| HSD3B6 | Rodent-specific isoform, may have distinct substrate specificity. | Studied in rat models of dihydrotestosterone formation. |
| HSD3B7 | Encodes a 3-beta-HSD isoform involved in bile acid synthesis. | Role in cholesterol metabolism; not a major steroidogenic enzyme. |
| CYP11A1 | Encodes cholesterol side-chain cleavage enzyme, upstream of 3-beta-HSD in steroidogenesis. | Provides substrate pregnenolone for 3-beta-HSD; co-expression studies. |
| CYP17A1 | Encodes 17-alpha-hydroxylase/17,20-lyase, downstream of 3-beta-HSD. | Inhibited by ketoconazole; used to study steroid pathway flux. |
| SRD5A1 | Encodes 5-alpha-reductase type 1, converts testosterone to DHT, downstream of 3-beta-HSD. | Studied in androgen-dependent tissues. |
| SRD5A2 | Encodes 5-alpha-reductase type 2, also downstream of 3-beta-HSD. | Target for prostate cancer research. |
| AKR1C3 | Encodes 17-beta-HSD type 5, can interconvert androgens, may interact with 3-beta-HSD pathway. | Peripheral androgen metabolism. |
| STAR | Encodes steroidogenic acute regulatory protein, facilitates cholesterol transport to mitochondria. | Upstream regulator of steroidogenesis; co-regulated with 3-beta-HSD. |
| NR5A1 | Encodes steroidogenic factor 1 (SF-1), a transcription factor regulating HSD3B genes. | Master regulator of steroidogenic gene expression. |
| INSL3 | Encodes insulin-like 3, involved in testicular descent, may affect steroidogenesis. | Not directly 3-beta-HSD but related to gonadal function. |
| POR | Encodes cytochrome P450 oxidoreductase, provides electrons to P450 enzymes in steroidogenesis. | Supports upstream and downstream reactions. |
| FDX1 | Encodes ferredoxin 1, electron carrier for mitochondrial P450 enzymes. | Essential for steroidogenesis; interacts with 3-beta-HSD pathway. |
| FDXR | Encodes ferredoxin reductase, reduces FDX1. | Supports mitochondrial steroidogenesis. |
How Is 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity Regulated?
The activity of 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) is regulated at multiple levels. Transcription of HSD3B genes is controlled by steroidogenic factor 1 (NR5A1) and other transcription factors in response to trophic hormones such as ACTH and LH. Post-translational modifications and interactions with phospholipids can modulate enzyme activity, as shown by phospholipase treatment affecting rat testicular androgen biosynthesis. Additionally, the availability of NADP+ and the redox state of the cell influence the reaction direction. In engineered yeast, self-sufficient biosynthesis of pregnenolone and progesterone was achieved by expressing 3-beta-HSD along with upstream enzymes, demonstrating that pathway flux can be regulated by enzyme expression levels.
3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSD3B2 | Congenital adrenal hyperplasia due to 3-beta-HSD deficiency | Knockout mouse or patient-derived iPSCs with point mutations |
| HSD3B1 | Breast and prostate cancer, androgen excess | Overexpression cell lines (MCF-7, LNCaP) and xenograft models |
| HSD3B1 | Polycystic ovary syndrome (PCOS) | Theca cell models with CRISPR knockout or knockdown |
| HSD3B2 | Adrenal insufficiency and salt-wasting | Adrenal cell lines (H295R) with knock-in of patient mutations |
| HSD3B1/2 | Pharmacological inhibition by ketoconazole | Enzyme activity assays in testicular microsomes |
Congenital Adrenal Hyperplasia and Endocrine Disorders
Mutations in HSD3B2, which encodes the type 2 3-beta-HSD enzyme, cause a rare form of congenital adrenal hyperplasia characterized by impaired cortisol and aldosterone synthesis, leading to salt-wasting and ambiguous genitalia in both sexes. The loss of 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity disrupts the conversion of delta-5 steroids to delta-4 steroids, resulting in accumulation of DHEA and other precursors.
Androgen Excess and Polycystic Ovary Syndrome
Increased 3-beta-HSD activity in peripheral tissues, particularly in adipose and skin, can contribute to androgen excess in conditions such as polycystic ovary syndrome (PCOS). The enzyme converts DHEA to androstenedione, which is then converted to testosterone, exacerbating hyperandrogenism.
Steroid-Dependent Cancers
Overexpression of HSD3B1 has been observed in breast and prostate cancers, where it enhances local production of estrogens and androgens, promoting tumor growth. Inhibition of 3-beta-HSD activity is therefore a potential therapeutic strategy for hormone-dependent cancers.
From 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of complete loss of 3-beta-HSD activity on steroidogenesis? | CRISPR knockout of HSD3B1/2 in H295R or primary adrenal cells |
| How do specific point mutations in HSD3B2 affect enzyme kinetics? | Point mutation knock-in in HEK293T cells followed by activity assay |
| Can a tagged version of 3-beta-HSD be used to study subcellular localization? | Knock-in of FLAG or GFP tag at the endogenous HSD3B1 locus |
| What is the impact of HSD3B1 overexpression on androgen production? | Overexpression of HSD3B1 in LNCaP or MCF-7 cells |
| Which genes interact with 3-beta-HSD in a genome-wide screen? | CRISPR library screening in steroidogenic cell lines |
| How does 3-beta-HSD activity affect drug response to ketoconazole? | Knockout of HSD3B1 in cancer cell lines followed by drug treatment |
How to Study the 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH generation assay | Dehydrogenase activity by absorbance at 340 nm | Kinetic characterization of wild-type and mutant 3-beta-HSD |
| Site-directed mutagenesis | Effect of specific amino acid substitutions on enzyme function | Identifying coenzyme specificity determinants |
| LC-MS/MS steroid profiling | Concentrations of steroid metabolites | Assessing pathway flux in cells and animal models |
| RNA-seq | Transcript levels of HSD3B genes and related steroidogenic enzymes | Tissue-specific expression and regulation |
| CRISPR knockout | Complete loss of gene function | Studying the role of HSD3B1/2 in steroidogenesis |
| CRISPR knock-in | Introduction of specific mutations or tags | Modeling patient mutations or tracking protein localization |
| Overexpression | Increased enzyme levels | Investigating the effects of 3-beta-HSD overexpression in cancer cells |
| CRISPR library screening | Genome-wide identification of genes affecting steroidogenesis | Discovering novel regulators of 3-beta-HSD activity |
Enzyme Activity Assays
The dehydrogenase activity of 3-beta-HSD can be measured spectrophotometrically by monitoring the reduction of NADP+ to NADPH at 340 nm using a suitable 3-beta-hydroxysteroid substrate such as pregnenolone or DHEA. This assay is widely used to characterize wild-type and mutant enzymes, and to screen for inhibitors like ketoconazole.
Site-Directed Mutagenesis and Structural Analysis
To identify residues critical for NADP+ specificity and catalysis, site-directed mutagenesis is performed on HSD3B1 or HSD3B2, followed by kinetic analysis. Crystallography or homology modeling can provide structural insights into the coenzyme-binding pocket and substrate recognition.
Gene Expression Profiling
Quantitative RT-PCR and RNA-seq are used to measure HSD3B mRNA levels in tissues and cell lines under different conditions, such as hormone stimulation or disease states. This helps correlate enzyme expression with steroidogenic output.
Metabolite Analysis by Mass Spectrometry
LC-MS/MS or GC-MS can quantify steroid metabolites (e.g., progesterone, androstenedione) in culture media or serum to assess 3-beta-HSD activity in intact cells or animal models. This approach is essential for studying pathway flux and drug effects.
How CRISPR Can Be Used to Study GO:0000253 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity
Knockout
CRISPR-Cas9 knockout of HSD3B1 or HSD3B2 in steroidogenic cell lines (e.g., H295R, LNCaP) can abolish 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity, leading to accumulation of delta-5 steroids and reduced production of downstream hormones. Such models are valuable for studying the consequences of enzyme deficiency and for validating drug targets.
Point Mutation
Introducing patient-derived point mutations (e.g., in HSD3B2) via CRISPR base editing or homology-directed repair allows researchers to dissect the impact of specific amino acid changes on enzyme kinetics and substrate specificity. This approach can replicate congenital adrenal hyperplasia phenotypes in vitro.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins at the endogenous HSD3B1 locus enables real-time tracking of enzyme localization and interaction partners using imaging and immunoprecipitation. This is particularly useful for studying mitochondrial and microsomal targeting of 3-beta-HSD.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of HSD3B1 can model the elevated enzyme levels seen in breast and prostate cancers, where increased 3-beta-HSD activity drives intratumoral androgen and estrogen synthesis. These models are used to test the efficacy of 3-beta-HSD inhibitors.
How EDITGENE Supports 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity Research
Researchers studying 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity-related genes often need to determine whether a candidate gene is causally involved in steroidogenesis, endocrine disease, or cancer progression. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity research.
Frequently Asked Questions About 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity
What is 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity?
It is a molecular function (GO:0000253) that catalyzes the oxidation of a 3-beta-hydroxyl sterol to a 3-oxosterol using NADP+ as a cofactor, producing NADPH and H+.
What genes are involved in 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity?
The primary genes are HSD3B1 and HSD3B2, which encode the type 1 and type 2 isoforms of the bifunctional 3-beta-HSD enzyme.
What is the role of 3-beta-HSD in steroid hormone synthesis?
3-beta-HSD converts delta-5-3-beta-hydroxysteroids (e.g., pregnenolone, DHEA) to delta-4-3-ketosteroids (e.g., progesterone, androstenedione), a key step in the production of all steroid hormones.
How is 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity measured?
It is commonly measured by a spectrophotometric assay that monitors NADPH formation at 340 nm using a 3-beta-hydroxysteroid substrate.
What diseases are associated with defects in 3-beta-HSD activity?
Mutations in HSD3B2 cause congenital adrenal hyperplasia, while overexpression of HSD3B1 is linked to androgen excess and steroid-dependent cancers [2,5].
Can CRISPR be used to study 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity?
Yes, CRISPR knockout, knock-in, and overexpression models allow precise manipulation of HSD3B genes to study their function in steroidogenesis and disease [2,6].
What is the difference between 3-beta-HSD type 1 and type 2?
Type 1 (HSD3B1) is mainly expressed in placenta and peripheral tissues, while type 2 (HSD3B2) is expressed in adrenal cortex and gonads; they differ in tissue distribution and kinetic properties.
How does NADP+ specificity arise in 3-beta-HSD?
Specific residues in the Rossmann-fold domain of the enzyme determine preference for NADP+ over NAD+, as shown by site-directed mutagenesis studies.
Is 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity reversible?
Yes, the reaction is reversible, and the direction depends on the cellular redox state and substrate availability.
What model systems are used to study 3-beta-HSD?
Common models include H295R adrenal cells, LNCaP prostate cancer cells, and engineered yeast expressing steroidogenic enzymes.
Conclusion
GO:0000253, 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity, is a fundamental enzymatic function in steroid hormone biosynthesis, catalyzing the conversion of delta-5-3-beta-hydroxysteroids to delta-4-3-ketosteroids. Its dysregulation is implicated in endocrine disorders and hormone-dependent cancers, making it a critical target for research and therapeutic development [2,5]. Understanding the molecular mechanism, regulation, and disease relevance of this activity requires precise experimental models, which can be efficiently generated using CRISPR-based approaches [1,6].
References
- 1. Thomas JL et al.. 2003. Structure/function relationships responsible for coenzyme specificity and the isomerase activity of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase.. J Biol Chem 278(37):35483-90 PMID: 12832414
- 2. Simard J et al.. 1995. Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family.. J Steroid Biochem Mol Biol 55(5-6):489-505 PMID: 8547174
- 3. Ayub M et al.. 1987. Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs.. J Steroid Biochem 28(5):521-31 PMID: 2824931
- 4. Sauer LA et al.. 1994. Topology of 3 beta-hydroxy-5-ene-steroid dehydrogenase/delta 5-delta 4-isomerase in adrenal cortex mitochondria and microsomes.. Endocrinology 134(2):751-9 PMID: 8299570
- 5. Sanchez R et al.. 1994. Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family.. Mol Cell Endocrinol 103(1-2):29-38 PMID: 7958395
- 6. Pletnev VZ et al.. 2006. Rational proteomics V: structure-based mutagenesis has revealed key residues responsible for substrate recognition and catalysis by the dehydrogenase and isomerase activities in human 3beta-hydroxysteroid dehydrogenase/isomerase type 1.. J Steroid Biochem Mol Biol 101(1):50-60 PMID: 16889958
- 7. Cooke GM et al.. 1988. Phospholipases modulate the rat testicular androgen biosynthetic pathway in vitro.. Biol Reprod 39(2):329-39 PMID: 2846083
- 8. Duport C et al.. 1998. Self-sufficient biosynthesis of pregnenolone and progesterone in engineered yeast.. Nat Biotechnol 16(2):186-9 PMID: 9487528
